$GILD News

Does Gilead (GILD) Pairing With Nucleai Reveal a Deeper Shift in Its Oncology Strategy?

Is Gilead's Expanding HIV Portfolio a Growth Catalyst?

Gilead Sciences Has Quietly Become One of the Most Underrated Turnaround Stories in Healthcare. Here's Why Wall Street Is Excited.

Gilead yanks out a thorn in its side in major court ruling

Gilead Sciences (GILD): Buy, Sell, or Hold Post Q2 Earnings?

Can MacroGenics (MGNX) Turn Gilead Sciences (GILD)’s $10M Milestone Into a Major Pipeline Catalyst?

Gilead wins appeals court ruling against overseas drug imports

Court rules companies can't import Gilead medications from overseas in blow to AFP health programs

Gilead (GILD) Stock Still Looks Cheap On Sales Despite A 127% Run

Why Gilead Sciences (GILD) Is Back In The Spotlight

5 Must-Read Analyst Questions From Gilead Sciences’s Q2 Earnings Call

Gilead Sciences (GILD) Expands ADC Research With AI Tissue Analytics

MacroGenics Announces Achievement of $10 Million Milestone Following Gilead’s Exercise of Option to License Preclinical Bispecific Program

If You Invested $1000 In Gilead Sciences Stock 20 Years Ago, You Would Have This Much Today

GILD- An Attractive Biotech Stock with Solid Base Revenue Growth

GILD Q2 Earnings Call Raises Outlook on HIV and PrEP Strength

Gilead Slumps As Long-Term Uncertainty Clouds Massive HIV Beat

Gilead (GILD) Faces HIV Drug Access Criticism From AIDS Healthcare Foundation

RBC Capital Maintains Sector Perform on Gilead Sciences, Raises Price Target to $123

The Bull Case For Gilead Sciences (GILD) Could Change Following Deeper 2026 Losses Amid HIV, Oncology Growth